B-intervention	0	8	External
I-intervention	9	13	beam
I-intervention	14	25	accelerated
I-intervention	26	33	partial
I-intervention	34	40	breast
I-intervention	41	52	irradiation
O	53	59	versus
B-control	60	65	whole
I-control	66	72	breast
I-control	73	84	irradiation
O	85	90	after
O	91	97	breast
O	98	108	conserving
O	109	116	surgery
O	117	119	in
B-eligibility	120	125	women
I-eligibility	126	130	with
I-eligibility	131	137	ductal
I-eligibility	138	147	carcinoma
I-eligibility	148	150	in
I-eligibility	151	155	situ
I-eligibility	156	159	and
I-eligibility	160	164	node
I-eligibility	164	165	-
I-eligibility	165	173	negative
I-eligibility	174	180	breast
I-eligibility	181	187	cancer
O	188	189	(
O	189	194	RAPID
O	194	195	)
O	195	196	:
O	197	198	a
O	199	209	randomised
O	210	220	controlled
O	221	226	trial
O	226	227	.

O	228	233	Whole
O	234	240	breast
O	241	252	irradiation
O	253	262	delivered
O	263	267	once
O	268	271	per
O	272	275	day
O	276	280	over
O	281	282	3
O	282	283	-
O	283	284	5
O	285	290	weeks
O	291	296	after
O	297	303	breast
O	304	314	conserving
O	315	322	surgery
O	323	330	reduces
O	331	336	local
O	337	347	recurrence
O	348	352	with
O	353	357	good
O	358	366	cosmetic
O	367	374	results
O	374	375	.

O	376	387	Accelerated
O	388	395	partial
O	396	402	breast
O	403	414	irradiation
O	415	416	(
O	416	420	APBI
O	420	421	)
O	422	431	delivered
O	432	436	over
O	437	438	1
O	439	443	week
O	444	446	to
O	447	450	the
O	451	457	tumour
O	458	461	bed
O	462	465	was
O	466	475	developed
O	476	478	to
O	479	486	provide
O	487	488	a
O	489	493	more
O	494	504	convenient
O	505	514	treatment
O	514	515	.

O	516	518	In
O	519	523	this
O	524	529	trial
O	529	530	,
O	531	533	we
O	534	546	investigated
O	547	549	if
O	550	558	external
O	559	563	beam
O	564	568	APBI
O	569	572	was
O	573	576	non
O	576	577	-
O	577	585	inferior
O	586	588	to
O	589	594	whole
O	595	601	breast
O	602	613	irradiation
O	613	614	.

O	615	617	We
O	618	621	did
O	622	626	this
O	627	638	multicentre
O	638	639	,
O	640	650	randomised
O	650	651	,
O	652	655	non
O	655	656	-
O	656	667	inferiority
O	668	673	trial
O	674	676	in
O	677	679	33
O	680	686	cancer
O	687	694	centres
O	695	697	in
B-location	698	704	Canada
I-location	704	705	,
I-location	706	715	Australia
I-location	716	719	and
I-location	720	723	New
I-location	724	731	Zealand
O	731	732	.

O	733	738	Women
O	739	743	aged
B-age	744	746	40
I-age	747	752	years
I-age	753	755	or
I-age	756	761	older
B-eligibility	762	766	with
I-eligibility	767	773	ductal
I-eligibility	774	783	carcinoma
I-eligibility	784	786	in
I-eligibility	787	791	situ
I-eligibility	792	794	or
I-eligibility	795	799	node
I-eligibility	799	800	-
I-eligibility	800	808	negative
I-eligibility	809	815	breast
I-eligibility	816	822	cancer
I-eligibility	823	830	treated
I-eligibility	831	833	by
I-eligibility	834	840	breast
I-eligibility	841	851	conserving
I-eligibility	852	859	surgery
O	860	864	were
O	865	873	randomly
O	874	882	assigned
O	883	884	(
O	884	885	1
O	885	886	:
O	886	887	1
O	887	888	)
O	889	891	to
O	892	899	receive
O	900	906	either
O	907	915	external
O	916	920	beam
O	921	925	APBI
O	926	927	(
O	927	929	38
O	929	930	·
O	930	931	5
O	932	934	Gy
O	935	937	in
O	938	941	ten
O	942	951	fractions
O	952	961	delivered
O	962	967	twice
O	968	971	per
O	972	975	day
O	976	980	over
O	981	982	5
O	982	983	-
O	983	984	8
O	985	989	days
O	989	990	)
O	991	993	or
O	994	999	whole
O	1000	1006	breast
O	1007	1018	irradiation
O	1019	1020	(
O	1020	1022	42
O	1022	1023	·
O	1023	1024	5
O	1025	1027	Gy
O	1028	1030	in
O	1031	1033	16
O	1034	1043	fractions
O	1044	1048	once
O	1049	1052	per
O	1053	1056	day
O	1057	1061	over
O	1062	1064	21
O	1065	1069	days
O	1069	1070	,
O	1071	1073	or
O	1074	1076	50
O	1077	1079	Gy
O	1080	1082	in
O	1083	1085	25
O	1086	1095	fractions
O	1096	1100	once
O	1101	1104	per
O	1105	1108	day
O	1109	1113	over
O	1114	1116	35
O	1117	1121	days
O	1121	1122	)
O	1122	1123	.

O	1124	1132	Patients
O	1133	1136	and
O	1137	1146	clinicans
O	1147	1151	were
O	1152	1155	not
O	1156	1162	masked
O	1163	1165	to
O	1166	1175	treatment
O	1176	1186	assignment
O	1186	1187	.

O	1188	1191	The
O	1192	1199	primary
O	1200	1207	outcome
O	1208	1211	was
B-outcome-Measure	1212	1223	ipsilateral
I-outcome-Measure	1224	1230	breast
I-outcome-Measure	1231	1237	tumour
I-outcome-Measure	1238	1248	recurrence
I-outcome-Measure	1249	1250	(
I-outcome-Measure	1250	1254	IBTR
I-outcome-Measure	1254	1255	)
O	1255	1256	,
O	1257	1265	analysed
O	1266	1268	by
O	1269	1278	intention
O	1279	1281	to
O	1282	1287	treat
O	1287	1288	.

O	1289	1292	The
O	1293	1298	trial
O	1299	1302	was
O	1303	1311	designed
O	1312	1314	on
O	1315	1318	the
O	1319	1324	basis
O	1325	1327	of
O	1328	1330	an
O	1331	1339	expected
O	1340	1341	5
O	1342	1346	year
O	1347	1351	IBTR
O	1352	1356	rate
O	1357	1359	of
O	1360	1361	1
O	1361	1362	·
O	1362	1363	5
O	1363	1364	%
O	1365	1367	in
O	1368	1371	the
O	1372	1377	whole
O	1378	1384	breast
O	1385	1396	irradiation
O	1397	1402	group
O	1403	1407	with
O	1408	1410	85
O	1410	1411	%
O	1412	1417	power
O	1418	1420	to
O	1421	1428	exclude
O	1429	1430	a
O	1431	1432	1
O	1432	1433	·
O	1433	1434	5
O	1434	1435	%
O	1436	1444	increase
O	1445	1447	in
O	1448	1451	the
O	1452	1456	APBI
O	1457	1462	group
O	1462	1463	;
O	1464	1467	non
O	1467	1468	-
O	1468	1479	inferiority
O	1480	1483	was
O	1484	1489	shown
O	1490	1492	if
O	1493	1496	the
O	1497	1502	upper
O	1503	1508	limit
O	1509	1511	of
O	1512	1515	the
O	1516	1519	two
O	1519	1520	-
O	1520	1525	sided
O	1526	1528	90
O	1528	1529	%
O	1530	1532	CI
O	1533	1536	for
O	1537	1540	the
O	1541	1545	IBTR
O	1546	1552	hazard
O	1553	1558	ratio
O	1559	1560	(
O	1560	1562	HR
O	1562	1563	)
O	1564	1567	was
O	1568	1572	less
O	1573	1577	than
O	1578	1579	2
O	1579	1580	·
O	1580	1582	02
O	1582	1583	.

O	1584	1588	This
O	1589	1594	trial
O	1595	1597	is
O	1598	1608	registered
O	1609	1613	with
O	1614	1628	ClinicalTrials
O	1628	1629	.
O	1629	1632	gov
O	1632	1633	,
O	1634	1645	NCT00282035
O	1645	1646	.

O	1647	1654	Between
O	1655	1658	Feb
O	1659	1660	7
O	1660	1661	,
O	1662	1666	2006
O	1666	1667	,
O	1668	1671	and
O	1672	1676	July
O	1677	1679	15
O	1679	1680	,
O	1681	1685	2011
O	1685	1686	,
O	1687	1689	we
O	1690	1698	enrolled
B-total-participants	1699	1703	2135
O	1704	1709	women
O	1709	1710	.

B-intervention-participants	1711	1715	1070
O	1716	1720	were
O	1721	1729	randomly
O	1730	1738	assigned
O	1739	1741	to
O	1742	1749	receive
O	1750	1754	APBI
O	1755	1758	and
B-control-participants	1759	1763	1065
O	1764	1768	were
O	1769	1777	assigned
O	1778	1780	to
O	1781	1788	receive
O	1789	1794	whole
O	1795	1801	breast
O	1802	1813	irradiation
O	1813	1814	.

O	1815	1818	Six
O	1819	1827	patients
O	1828	1830	in
O	1831	1834	the
O	1835	1839	APBI
O	1840	1845	group
O	1846	1854	withdrew
O	1855	1861	before
O	1862	1871	treatment
O	1871	1872	,
O	1873	1877	four
O	1878	1882	more
O	1883	1886	did
O	1887	1890	not
O	1891	1898	receive
O	1899	1911	radiotherapy
O	1911	1912	,
O	1913	1916	and
O	1917	1919	16
O	1920	1928	patients
O	1929	1937	received
O	1938	1943	whole
O	1944	1950	breast
O	1951	1962	irradiation
O	1962	1963	.

O	1964	1966	In
O	1967	1970	the
O	1971	1976	whole
O	1977	1983	breast
O	1984	1995	irradiation
O	1996	2001	group
O	2001	2002	,
O	2003	2005	16
O	2006	2014	patients
O	2015	2023	withdrew
O	2023	2024	,
O	2025	2028	and
O	2029	2032	two
O	2033	2037	more
O	2038	2041	did
O	2042	2045	not
O	2046	2053	receive
O	2054	2066	radiotherapy
O	2066	2067	.

O	2068	2070	In
O	2071	2074	the
O	2075	2079	APBI
O	2080	2085	group
O	2085	2086	,
O	2087	2088	a
O	2089	2096	further
O	2097	2099	14
O	2100	2108	patients
O	2109	2113	were
O	2114	2118	lost
O	2119	2121	to
O	2122	2128	follow
O	2128	2129	-
O	2129	2131	up
O	2132	2135	and
O	2136	2140	nine
O	2141	2149	patients
O	2150	2158	withdrew
O	2159	2165	during
O	2166	2169	the
O	2170	2176	follow
O	2176	2177	-
O	2177	2179	up
O	2180	2186	period
O	2186	2187	.

O	2188	2190	In
O	2191	2194	the
O	2195	2200	whole
O	2201	2207	breast
O	2208	2219	irradiation
O	2220	2225	group
O	2225	2226	,
O	2227	2229	20
O	2230	2238	patients
O	2239	2243	were
O	2244	2248	lost
O	2249	2251	to
O	2252	2258	follow
O	2258	2259	-
O	2259	2261	up
O	2262	2265	and
O	2266	2268	35
O	2269	2277	withdrew
O	2278	2284	during
O	2285	2291	follow
O	2291	2292	-
O	2292	2294	up
O	2294	2295	.

O	2296	2302	Median
O	2303	2309	follow
O	2309	2310	-
O	2310	2312	up
O	2313	2316	was
O	2317	2318	8
O	2318	2319	·
O	2319	2320	6
O	2321	2326	years
O	2327	2328	(
O	2328	2331	IQR
O	2332	2333	7
O	2333	2334	·
O	2334	2335	3
O	2335	2336	-
O	2336	2337	9
O	2337	2338	·
O	2338	2339	9
O	2339	2340	)
O	2340	2341	.

O	2342	2345	The
B-outcome	2346	2347	8
I-outcome	2347	2348	-
I-outcome	2348	2352	year
I-outcome	2353	2363	cumulative
I-outcome	2364	2369	rates
I-outcome	2370	2372	of
I-outcome	2373	2377	IBTR
O	2378	2382	were
B-iv-bin-percent	2383	2384	3
I-iv-bin-percent	2384	2385	·
I-iv-bin-percent	2385	2386	0
I-iv-bin-percent	2386	2387	%
O	2388	2389	(
O	2389	2391	95
O	2391	2392	%
O	2393	2395	CI
O	2396	2397	1
O	2397	2398	·
O	2398	2399	9
O	2399	2400	-
O	2400	2401	4
O	2401	2402	·
O	2402	2403	0
O	2403	2404	)
O	2405	2407	in
O	2408	2411	the
O	2412	2416	APBI
O	2417	2422	group
O	2423	2426	and
B-cv-bin-percent	2427	2428	2
I-cv-bin-percent	2428	2429	·
I-cv-bin-percent	2429	2430	8
I-cv-bin-percent	2430	2431	%
O	2432	2433	(
O	2433	2434	1
O	2434	2435	·
O	2435	2436	8
O	2436	2437	-
O	2437	2438	3
O	2438	2439	·
O	2439	2440	9
O	2440	2441	)
O	2442	2444	in
O	2445	2448	the
O	2449	2454	whole
O	2455	2461	breast
O	2462	2473	irradiation
O	2474	2479	group
O	2479	2480	.

O	2481	2484	The
B-outcome	2485	2487	HR
O	2488	2491	for
O	2492	2496	APBI
O	2497	2503	versus
O	2504	2509	whole
O	2510	2516	breast
O	2517	2526	radiation
O	2527	2530	was
O	2531	2532	1
O	2532	2533	·
O	2533	2535	27
O	2536	2537	(
O	2537	2539	90
O	2539	2540	%
O	2541	2543	CI
O	2544	2545	0
O	2545	2546	·
O	2546	2548	84
O	2548	2549	-
O	2549	2550	1
O	2550	2551	·
O	2551	2553	91
O	2553	2554	)
O	2554	2555	.

B-outcome	2556	2561	Acute
I-outcome	2562	2571	radiation
I-outcome	2572	2580	toxicity
O	2581	2582	(
O	2582	2587	grade
O	2588	2589	≥
O	2589	2590	2
O	2590	2591	,
O	2592	2598	within
O	2599	2600	3
O	2601	2607	months
O	2608	2610	of
O	2611	2623	radiotherapy
O	2624	2629	start
O	2629	2630	)
O	2631	2639	occurred
O	2640	2644	less
O	2645	2655	frequently
O	2656	2658	in
O	2659	2667	patients
O	2668	2675	treated
O	2676	2680	with
O	2681	2685	APBI
O	2686	2687	(
B-iv-bin-abs	2687	2690	300
O	2691	2692	[
B-iv-bin-percent	2692	2694	28
I-iv-bin-percent	2694	2695	%
O	2695	2696	]
O	2697	2699	of
B-intervention-participants	2700	2704	1070
O	2705	2713	patients
O	2713	2714	)
O	2715	2719	than
O	2720	2725	whole
O	2726	2732	breast
O	2733	2744	irradiation
O	2745	2746	(
B-cv-bin-abs	2746	2749	484
O	2750	2751	[
B-cv-bin-percent	2751	2753	45
I-cv-bin-percent	2753	2754	%
O	2754	2755	]
O	2756	2758	of
B-control-participants	2759	2763	1065
O	2764	2772	patients
O	2772	2773	,
O	2774	2775	p
O	2775	2776	<
O	2776	2777	0
O	2777	2778	·
O	2778	2782	0001
O	2782	2783	)
O	2783	2784	.

B-outcome	2785	2789	Late
I-outcome	2790	2799	radiation
I-outcome	2800	2808	toxicity
O	2809	2810	(
O	2810	2815	grade
O	2816	2817	≥
O	2817	2818	2
O	2818	2819	,
O	2820	2825	later
O	2826	2830	than
O	2831	2832	3
O	2833	2839	months
O	2839	2840	)
O	2841	2844	was
O	2845	2849	more
O	2850	2856	common
O	2857	2859	in
O	2860	2868	patients
O	2869	2876	treated
O	2877	2881	with
O	2882	2886	APBI
O	2887	2888	(
B-iv-bin-abs	2888	2891	346
O	2892	2893	[
B-iv-bin-percent	2893	2895	32
I-iv-bin-percent	2895	2896	%
O	2896	2897	]
O	2898	2900	of
B-intervention-participants	2901	2905	1070
O	2906	2914	patients
O	2914	2915	)
O	2916	2920	than
O	2921	2926	whole
O	2927	2933	breast
O	2934	2945	irradiation
O	2946	2947	(
B-cv-bin-abs	2947	2950	142
O	2951	2952	[
B-cv-bin-percent	2952	2954	13
I-cv-bin-percent	2954	2955	%
O	2955	2956	]
O	2957	2959	of
B-control-participants	2960	2964	1065
O	2965	2973	patients
O	2973	2974	;
O	2975	2976	p
O	2976	2977	<
O	2977	2978	0
O	2978	2979	·
O	2979	2983	0001
O	2983	2984	)
O	2984	2985	.

B-outcome	2986	2993	Adverse
I-outcome	2994	3002	cosmesis
O	3003	3004	(
O	3004	3011	defined
O	3012	3014	as
O	3015	3019	fair
O	3020	3022	or
O	3023	3027	poor
O	3027	3028	)
O	3029	3032	was
O	3033	3037	more
O	3038	3044	common
O	3045	3047	in
O	3048	3056	patients
O	3057	3064	treated
O	3065	3069	with
O	3070	3074	APBI
O	3075	3079	than
O	3080	3082	in
O	3083	3088	those
O	3089	3096	treated
O	3097	3099	by
O	3100	3105	whole
O	3106	3112	breast
O	3113	3124	irradiation
B-outcome	3125	3127	at
I-outcome	3128	3129	3
I-outcome	3130	3135	years
O	3136	3137	(
O	3137	3145	absolute
O	3146	3156	difference
O	3156	3157	,
O	3158	3160	11
O	3160	3161	·
O	3161	3162	3
O	3162	3163	%
O	3163	3164	,
O	3165	3167	95
O	3167	3168	%
O	3169	3171	CI
O	3172	3173	7
O	3173	3174	·
O	3174	3175	5
O	3175	3176	-
O	3176	3178	15
O	3178	3179	·
O	3179	3180	0
O	3180	3181	)
O	3181	3182	,
B-outcome	3183	3184	5
I-outcome	3185	3190	years
O	3191	3192	(
O	3192	3194	16
O	3194	3195	·
O	3195	3196	5
O	3196	3197	%
O	3197	3198	,
O	3199	3201	12
O	3201	3202	·
O	3202	3203	5
O	3203	3204	-
O	3204	3206	20
O	3206	3207	·
O	3207	3208	4
O	3208	3209	)
O	3209	3210	,
O	3211	3214	and
B-outcome	3215	3216	7
I-outcome	3217	3222	years
O	3223	3224	(
O	3224	3226	17
O	3226	3227	·
O	3227	3228	7
O	3228	3229	%
O	3229	3230	,
O	3231	3233	12
O	3233	3234	·
O	3234	3235	9
O	3235	3236	-
O	3236	3238	22
O	3238	3239	·
O	3239	3240	3
O	3240	3241	)
O	3241	3242	.

O	3243	3251	External
O	3252	3256	beam
O	3257	3261	APBI
O	3262	3265	was
O	3266	3269	non
O	3269	3270	-
O	3270	3278	inferior
O	3279	3281	to
O	3282	3287	whole
O	3288	3294	breast
O	3295	3306	irradiation
O	3307	3309	in
O	3310	3320	preventing
O	3321	3325	IBTR
O	3325	3326	.

O	3327	3335	Although
O	3336	3340	less
B-outcome	3341	3346	acute
I-outcome	3347	3355	toxicity
O	3356	3359	was
O	3360	3368	observed
O	3368	3369	,
O	3370	3373	the
O	3374	3381	regimen
O	3382	3386	used
O	3387	3390	was
O	3391	3401	associated
O	3402	3406	with
O	3407	3409	an
O	3410	3418	increase
O	3419	3421	in
O	3422	3430	moderate
O	3431	3435	late
O	3436	3444	toxicity
O	3445	3448	and
O	3449	3456	adverse
O	3457	3465	cosmesis
O	3465	3466	,
O	3467	3472	which
O	3473	3478	might
O	3479	3481	be
O	3482	3489	related
O	3490	3492	to
O	3493	3496	the
O	3497	3502	twice
O	3503	3506	per
O	3507	3510	day
O	3511	3520	treatment
O	3520	3521	.

O	3522	3527	Other
O	3528	3538	approaches
O	3538	3539	,
O	3540	3544	such
O	3545	3547	as
O	3548	3557	treatment
O	3558	3562	once
O	3563	3566	per
O	3567	3570	day
O	3570	3571	,
O	3572	3577	might
O	3578	3581	not
O	3582	3591	adversely
O	3592	3598	affect
O	3599	3607	cosmesis
O	3608	3611	and
O	3612	3618	should
O	3619	3621	be
O	3622	3629	studied
O	3629	3630	.

O	3631	3639	Canadian
O	3640	3650	Institutes
O	3651	3654	for
O	3655	3661	Health
O	3662	3670	Research
O	3671	3674	and
O	3675	3683	Canadian
O	3684	3690	Breast
O	3691	3697	Cancer
O	3698	3706	Research
O	3707	3715	Alliance
O	3715	3716	.
